23 April 2021 - Agencies underscore confidence in vaccine’s safety and effectiveness following data assessment; available data suggest potential blood clots are very rare events.

Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. FDA and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

Read FDA press release